We are live on ! Find out more
NVET

Nexvet Biopharma plc Ordinary Shares
NVET

Delisted

NVET was delisted on the 28th of July, 2017.

Back to rankings

18 hedge funds and large institutions have $21.6M invested in Nexvet Biopharma plc Ordinary Shares in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more funds holding

Funds holding: 17 → 18 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less capital invested

Capital invested by funds: $23.8M → $21.6M (-$2.19M)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
18
Holders Change
+1
Holders Change %
+5.88%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
2
Reduced
6
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$454K
2
Creative Planning
Creative Planning
Kansas
+$4.13K
3
TRCT
Tower Research Capital (TRC)
New York
+$466

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management II
California
-$22.5K
2
CI
Cowen Inc
New York
-$12.8K
3
Deutsche Bank
Deutsche Bank
Germany
-$2.48K
4
Bank of America
Bank of America
North Carolina
-$2.31K
5
Citigroup
Citigroup
New York
-$2.06K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$9.72M – – –
BC
2
Broadfin Capital
New York
$4.21M +$454K +109,945 +11%
FCMI
3
Foresite Capital Management II
California
$3.34M -$22.5K -5,460 -0.6%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$2.97M – – –
BC
5
Boxer Capital
California
$578K – – –
LLC
6
Latimer Light Capital
New York
$392K – – –
BCM
7
Bridgeway Capital Management
Texas
$163K – – –
Norges Bank
8
Norges Bank
Norway
$130K – – –
CI
9
Cowen Inc
New York
$43K -$12.8K -3,100 -21%
Bank of America
10
Bank of America
North Carolina
$35K -$2.31K -560 -6%
Citigroup
11
Citigroup
New York
$19K -$2.06K -500 -9%
Morgan Stanley
12
Morgan Stanley
New York
$12K – – –
UBS Group
13
UBS Group
Switzerland
$10K -$1.43K -346 -11%
Creative Planning
14
Creative Planning
Kansas
$4K +$4.13K +1,000 New
TRCT
15
Tower Research Capital (TRC)
New York
$3K +$466 +113 +16%
Deutsche Bank
16
Deutsche Bank
Germany
$2K -$2.48K -600 -51%
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
$2K – – –

NVET Hedge Fund Activity: Q4 2016 in Review

18 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q4 2016, worth a combined $21.6M — down 9.2% from $23.8M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NVET positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $454K. The largest seller was Foresite Capital Management II, cutting an estimated $22.5K.

  • 18 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q4 2016, up from 17 in Q3 2016.
  • Funds reported $21.6M of Nexvet Biopharma plc Ordinary Shares stock for Q4 2016, down 9.2% quarter-over-quarter.
  • 1 fund opened new Nexvet Biopharma plc Ordinary Shares positions in Q4 2016 and 0 closed out, a net change of +1 holder.
  • The largest Nexvet Biopharma plc Ordinary Shares buyer in Q4 2016 was Broadfin Capital, an estimated $454K added.
  • The largest Nexvet Biopharma plc Ordinary Shares seller in Q4 2016 was Foresite Capital Management II, an estimated $22.5K sold.

Based on aggregated 13F filings for Q4 2016.